328 related articles for article (PubMed ID: 37781031)
1. Apolipoproteins as potential communicators play an essential role in the pathogenesis and treatment of early atherosclerosis.
Li Y; Luo X; Hua Z; Xue X; Wang X; Pang M; Wang T; Lyu A; Liu Y
Int J Biol Sci; 2023; 19(14):4493-4510. PubMed ID: 37781031
[TBL] [Abstract][Full Text] [Related]
2. Lipin-1 contributes to modified low-density lipoprotein-elicited macrophage pro-inflammatory responses.
Navratil AR; Vozenilek AE; Cardelli JA; Green JM; Thomas MJ; Sorci-Thomas MG; Orr AW; Woolard MD
Atherosclerosis; 2015 Oct; 242(2):424-32. PubMed ID: 26288136
[TBL] [Abstract][Full Text] [Related]
3. Nonlinear dynamics of early atherosclerotic plaque formation may determine the efficacy of high density lipoproteins (HDL) in plaque regression.
Chalmers AD; Bursill CA; Myerscough MR
PLoS One; 2017; 12(11):e0187674. PubMed ID: 29161303
[TBL] [Abstract][Full Text] [Related]
4. The Initial Human Atherosclerotic Lesion and Lipoprotein Modification-A Deep Connection.
Torzewski M
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34768918
[TBL] [Abstract][Full Text] [Related]
5. Triglyceride-rich lipoproteins and cardiovascular diseases.
Xu D; Xie L; Cheng C; Xue F; Sun C
Front Endocrinol (Lausanne); 2024; 15():1409653. PubMed ID: 38883601
[TBL] [Abstract][Full Text] [Related]
6. Lipoprotein ability to exchange and remove lipids from model membranes as a function of fatty acid saturation and presence of cholesterol.
Waldie S; Sebastiani F; Browning K; Maric S; Lind TK; Yepuri N; Darwish TA; Moulin M; Strohmeier G; Pichler H; Skoda MWA; Maestro A; Haertlein M; Forsyth VT; Bengtsson E; Malmsten M; Cárdenas M
Biochim Biophys Acta Mol Cell Biol Lipids; 2020 Oct; 1865(10):158769. PubMed ID: 32712249
[TBL] [Abstract][Full Text] [Related]
7. High-density lipoprotein or cyclodextrin extraction of cholesterol from aggregated LDL reduces foam cell formation.
Singh RK; Lund FW; Haka AS; Maxfield FR
J Cell Sci; 2019 Dec; 132(23):. PubMed ID: 31719160
[TBL] [Abstract][Full Text] [Related]
8. Exogenous GM3 ganglioside inhibits atherosclerosis via multiple steps: A potential atheroprotective drug.
Ao M; Wang K; Zhou X; Chen G; Zhou Y; Wei B; Shao W; Huang J; Liao H; Wang Z; Sun Y; Zeng S; Chen Y
Pharmacol Res; 2019 Oct; 148():104445. PubMed ID: 31526872
[TBL] [Abstract][Full Text] [Related]
9. A Novel Candidate for Prevention and Treatment of Atherosclerosis: Urolithin B Decreases Lipid Plaque Deposition in apoE
Zhao W; Wang L; Haller V; Ritsch A
Mol Nutr Food Res; 2019 May; 63(10):e1800887. PubMed ID: 30762936
[TBL] [Abstract][Full Text] [Related]
10. Elimination of Ox-LDL through the liver inhibits advanced atherosclerotic plaque progression.
Wang Z; Guo X; Zhang Q; Du G; Zeng Z; Zheng C; Wei Y
Int J Med Sci; 2021; 18(16):3652-3664. PubMed ID: 34790037
[No Abstract] [Full Text] [Related]
11. Aggregation and fusion of low-density lipoproteins in vivo and in vitro.
Lu M; Gursky O
Biomol Concepts; 2013 Oct; 4(5):501-18. PubMed ID: 25197325
[TBL] [Abstract][Full Text] [Related]
12. Guanmaitong Granule Attenuates Atherosclerosis by Inhibiting Inflammatory Immune Response in ApoE
Yang M; Jiao H; Li Y; Zhang L; Zhang J; Zhong X; Xue Y
Drug Des Devel Ther; 2022; 16():3145-3168. PubMed ID: 36148321
[TBL] [Abstract][Full Text] [Related]
13. Oxidative modification of lipoproteins.
Arai H
Subcell Biochem; 2014; 77():103-14. PubMed ID: 24374922
[TBL] [Abstract][Full Text] [Related]
14. Deletion of the angiotensin II type 1a receptor prevents atherosclerotic plaque rupture in apolipoprotein E-/- mice.
Aono J; Suzuki J; Iwai M; Horiuchi M; Nagai T; Nishimura K; Inoue K; Ogimoto A; Okayama H; Higaki J
Arterioscler Thromb Vasc Biol; 2012 Jun; 32(6):1453-9. PubMed ID: 22460554
[TBL] [Abstract][Full Text] [Related]
15. Effects of PKF275-055, a dipeptidyl peptidase-4 inhibitor, on the development of atherosclerotic lesions in apolipoprotein E-null mice.
Terasaki M; Nagashima M; Watanabe T; Nohtomi K; Mori Y; Miyazaki A; Hirano T
Metabolism; 2012 Jul; 61(7):974-7. PubMed ID: 22225957
[TBL] [Abstract][Full Text] [Related]
16. Cholesterol Acceptors Regulate the Lipidome of Macrophage Foam Cells.
Paul A; Lydic TA; Hogan R; Goo YH
Int J Mol Sci; 2019 Aug; 20(15):. PubMed ID: 31382484
[TBL] [Abstract][Full Text] [Related]
17. The Pathogenic Role of Foam Cells in Atherogenesis: Do They Represent Novel Therapeutic Targets?
Lisco G; Giagulli VA; De Pergola G; Guastamacchia E; Jirillo E; Triggiani V
Endocr Metab Immune Disord Drug Targets; 2022 Aug; 22(7):765-777. PubMed ID: 34994321
[TBL] [Abstract][Full Text] [Related]
18. Lipid droplet-associated proteins in atherosclerosis (Review).
Plakkal Ayyappan J; Paul A; Goo YH
Mol Med Rep; 2016 Jun; 13(6):4527-34. PubMed ID: 27082419
[TBL] [Abstract][Full Text] [Related]
19. Macrophage foam cell formation during early atherogenesis is determined by the balance between pro-oxidants and anti-oxidants in arterial cells and blood lipoproteins.
Aviram M
Antioxid Redox Signal; 1999; 1(4):585-94. PubMed ID: 11233155
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
